Common blood pressure medicine blocks molecule that can trigger the disease
A drug commonly used to control high blood pressure may also help prevent the onset of Type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida (UF) in Gainesville.
The study was published online this week in the Journal of Clinical Investigation.
“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, MD, a researcher at the Barbara Davis Center for Childhood Diabetes and associate professor of medicine at CU Anschutz. “We made this discovery using a supercomputer, on the lab bench, in mice and in humans.”
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children. It is on the World Health Organization’s list of essential drugs.
But like many drugs used for one condition, Michels and his colleagues found it useful for something totally unrelated.
Some 60 percent of people at risk of getting Type 1 diabetes possess the DQ8 molecule which significantly increases the chance of getting the disease. The researchers believed that if they could block specifically the DQ8 molecule they could also block the onset of the disease.
“All drugs have off-target effects. If you take too much acetaminophen you can hurt your liver,” Michels said. “We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove.”
After running thousands of drugs through the supercomputer, they found that methyldopa not only blocked DQ8, but it didn’t harm the immune function of other cells like many immunosuppressant drugs do.
The research spanned 10 years and its efficacy was shown in mice and in 20 Type 1 diabetes patients who took part in a clinical trial at the Barbara Davis Center at the University of Colorado School of Medicine.
“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes,” Michels said. “The goal with this drug is to delay or prevent the onset of the disease among those at risk.”
The drug is taken orally, three times a day.
Implications for treatment
Michels and UF Health researcher David Ostrov, PhD, hope this same approach of blocking specific molecules can be used in other diseases.
“This study has significant implications for treatment of diabetes and also other autoimmune diseases,” said Ostrov, associate professor of pathology, immunology and laboratory medicine in the UF College of Medicine and a member of the UF Health Cancer Center, Genetics Institute and Center for NeuroGenetics. “This study suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”
The next step will be a larger clinical trial sponsored by the National Institutes of Health in spring.
“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at risk for the disease,” Michels said. “This is very significant development.”
The Latest on: Type 1 diabetes
via Google News
The Latest on: Type 1 diabetes
- Type 2 diabetes: Know your risks on December 9, 2018 at 11:31 pm
Sneaky and silent are two adjectives health care providers use when talking about Type 2 diabetes. The American Diabetes Association estimates that 30 million people have Type 2 diabetes and 7 million ... […]
- Fear impacts quality of life for young adults with type 1 diabetes on December 9, 2018 at 12:42 am
(HealthDay)—Fear of complications and frustration at the amount of time required to manage type 1 diabetes impact the quality of life of young adults with the disease, according to a study ... […]
- Potential Risks of Cannabis Use in People with Type 1 on December 7, 2018 at 5:17 pm
In an effort to demystify at least one aspect of cannabis use, this study aims to evaluate the comparative occurrence rate of DKA in people with type 1 diabetes who do and do not use cannabis. As this ... […]
- Genetic Risk Score for Type 1 Diabetes Predicts Progression of Disease on December 7, 2018 at 5:17 pm
Study focuses on score accuracy to improve prediction models for the better. Identifying patients at risk for developing type 1 diabetes (T1D) can allow for prevention trials as well as study of the p... […]
- Hypoglycemia fear damages quality of life for young adults with type 1 diabetes on December 7, 2018 at 4:50 pm
“More than half of type 1 diabetes cases are diagnosed before the age of 21 years,” Denise A. Kent, PhD, RN, APN, a clinical instructor in the department of biobehavioral health science at the Univers... […]
- B-cell Subset Offers Potential New Therapy for Type 1 Diabetes on December 7, 2018 at 6:29 am
Scientists at the Baylor College of Medicine and the University of Michigan Medical School report that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 diabetes in ... […]
- High serum uromodulin levels suggest lower risk for coronary artery calcification in type 1 diabetes on December 6, 2018 at 9:36 am
Coronary artery calcification and diabetic kidney disease appear to develop more slowly in the presence of higher serum uromodulin concentrations in adults with type 1 diabetes, according to findings ... […]
- Subtype of immune B cells can delay type 1 diabetes onset in mice on December 6, 2018 at 6:04 am
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can ... […]
- Teen with Type 1 diabetes reminds classmates it's no laughing matter on November 30, 2018 at 1:24 pm
After getting a lot of questions and being bullied and shamed for her Type 1 diabetes, one 13-year-old girl from Maine says she's had enough. Now, she's taking things into her own hands on a mission t... […]
via Bing News